Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL196878 | 0.97 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL29179 | 0.97 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL954340 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL556980 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL28797563 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL3930010 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL2920316 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL7164452 | 0.94 | TDP1 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL8211513 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL689027 | 0.94 | TDP1 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5043485-A | — | — | None | — | — | JP | disclosed |
| US-7858791-B2 | Process for the preparation of cabergoline | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 2010-12-28 | — | — | US | disclosed |
| EP-1720869-B1 | PROCESS FOR THE PREPARATION OF CABERGOLINE | RICHTER GEDEON NYRT (HU) | 2010-05-26 | — | — | EP | disclosed |
| EP-2157859-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | Takeda Pharmaceutical Company Limited (JP) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008156757-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-24 | — | — | WO | disclosed |
| US-20070293677-A1 | Process for the Preparation of Cabergoline | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-12-20 | — | — | US | disclosed |
| JP-H0543485-A | SYNTHESIS OF SUBSTITUTED ALLYLBENZENE | HOKKO CHEM IND CO LTD | 1993-02-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293677-A1 | Process for the Preparation of Cabergoline | ERG, UBE2V1, CYP4A11 | CYP3A4 40/4885TDP1 1891/4885ESR1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.